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TIMOR MORTIS
Siddhartha Mukherjee,
The Emperor of All Maladies
(Scribner 2010)
Charles Angell

n the opening pages of The Emperor of All Maladies,
his narrative history of cancer research and
therapy, Mukherjee tells the reader that leukemia
“represents a special incarnation of cancer. Its pace,
its breathtaking, inexorable arc of growth forces rapid,
often drastic decisions; it is terrifying to experience,
terrifying to observe, and terrifying to treat.”What
Mukherjee says about leukemia could, from the point
of view of those afflicted, be said of any cancer.That
dark moment arrives, after the physician has given his
diagnosis, when all one can think to ask is “should I put

I

my affairs in order?” Up until the 1950s
the answer to the question was all too
frequently “yes.” However, in the last
several decades medical and biological
research has achieved significant new
understandings of the physiological,
chemical, and environmental etiology
of tumors. Researchers have developed
new therapeutic interventions that
have helped mitigate, if not cure, some
cancers. Patients afflicted with breast,
cervical, prostate and leukemia cancers
today have an improved chance of survival. But for those suffering from lung,
brain and pancreatic cancers the answer
too often remains “no.”
In a PBS Newshour interview (2-242011) with Betty Ann Bowser,
Mukherjee explains that he used a
leukemia patient, whom he calls Carla,
as a thread to link his narrative. Prior to
meeting Carla in her Mass General
Hospital room, he “mentally rehearsed
the conversation I would have with her.
There was, I noted ruefully, something
rehearsed and robotic even about my
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sympathy.” Mukherjee, ten months into
a two-year oncology fellowship notes
that he had already seen “dozens of
patients” in his care die.“The stories of
my patients consumed me, and the decisions I made haunted me.” He also notes
that his “day-to-day management of
cancer” ultimately gave him a “novice’s
hunger for history” and an urgent desire
to understand the historical genesis of
cancer and how that history shaped the
present, more highly developed, but still
very incomplete, understanding of the
malady. Carla, who faces her leukemia
with courage and dignity, benefits from
the advances but even so undergoes
great physical and mental suffering.
In tracing the history of cancer research,
Mukherjee advances some major
themes. The Emperor of All Maladies
examines the distinct (and often
opposing) roles played by surgeons,
chemotherapists/radiologists and, in
more recent decades, genetic/molecular
researchers.The most troubling theme
looks at the interplay between politics,

policy, and scientific research and
whether a “war” on cancer devoted to
discovering a cure should take precedence over a much broader spectrum
of research activities.This brief review
cannot hope to cover the broad range
of topics Mukharjee introduces; let me
focus on the advances in breast cancer
research and therapy to engage directly
the roles played by surgeons, chemotherapists and biological researchers and,
indirectly, the controversies that have
arisen out of the research.
Historically, breast cancer had been recognized since pharaonic times; surgical
removal of tumors provided the most
common method for treating the cancer. Until the discovery of anesthetics,
patients underwent almost intolerable
suffering.The prevailing practice was
to remove not only the tumor but
also much of the muscle and sinews
proximate—and sometimes not so proximate—to the tumor.“‘The patient
was a young lady whom I was loath to
disfigure,’” wrote William Halsted, a
Johns Hopkins practitioner of radical
mastectomy, who applied the term
“mistaken kindness” to surgeons who
hesitated in the face of metastatic breast
cancer to surgically remove pectoral,
shoulder, and rib muscles and strip
lymph nodes to create clean margins.
Gradually, another group of researchers
discovered that certain chemicals could
shrink tumors and retard their growth.
While surgeons as a cohort believed
the only way to stop cancer’s spread was
surgical removal of the cancerous tissue,
chemotherapists believed chemical
interventions offered a surer and less
physically damaging approach. Since
the chemicals destroyed healthy cells
as well as cancerous ones, the trick was
to develop a chemical tonic whose
toxins eliminated the cancerous cells
more quickly than they destroyed
healthy cells. In many instances it was
a near-run race where the cure might
present more problems than the disease.
The side effects—nausea, vomiting,
dehydration, hair loss—meant long term
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agonies for many women. For years
the prevailing practice was that a wide
spectrum of chemical toxins was the
most effective therapy and so doses
increased in magnitude with a concomitant increase in damaging side effects.
More recent discoveries, however, have
tended to indicate that the chemical
interventions should more narrowly
and precisely target tumors which often
respond better to specific chemical toxins rather than to a toxic smorgasbord
served to them.
Molecular biology and hormonal
research has opened new avenues for
treating cancer. Hiking in Scottish
highlands in the late 1890s, George
Beatson, a surgeon “trying to devise
new surgical methods to treat breast
cancer, had learned from shepherds that
the removal of ovaries from cows altered
their capacity to lactate and changed
the quality of their udders.” Beatson
did not understand the basis of this
phenomenon. (Edward Doisy’s discovery of the ovarian hormone estrogen
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lay several decades in the future.)
Intrigued by the unexplained connection between ovaries and breasts,
Beatson “surgically removed the ovaries
of three women with breast cancer….
[To] Beatson’s astonishment, his three
cases revealed marked responses to the
ovarian removal—the breast tumors
shrank dramatically.” But why?
Larger patient samples produced mixed
and puzzling therapeutic results; a surgical team in London found that only
two thirds of breast cancer patients
responded to the ovarian removal.
Why did some respond and some not?
Though Doisy discovered estrogen in
1929, it took until the 1960s for molecular researchers to discover that some
breast cancer cells had receptors hungry
for estrogen (ER positive) and thus
responsive to surgery that cut off the
supply of estrogen. Other women,
however, had cells lacking receptors
(ER negative) which were not estrogen
dependent and thus unresponsive
to ovarian removal. Moreover, owing

to side-effects, most notably osteoporosis, surgically removing a woman’s
ovaries became a much less frequent
treatment option.
Might there exist a pharmacological
therapy to “inhibit estrogen function?”
Believing that chemotherapy (which
had begun to exert its influence over
surgery) offered more promising therapeutic results, pharmaceutical companies had little interest in developing an
antiestrogen and were reluctant to
embark on an expensive and perhaps
unprofitable research program. Once
again, one of those serendipitous
moments that so often happen in scientific research emerged.A team of British
chemists working for the Imperial
Chemical Industries filed a patent for
ICI 46474, or tamoxifen, originally
intended as a birth control pill which,
instead of turning on the estrogen
receptor necessary for a contraceptive
drug, in fact turned it off. In an “aha!”
moment,ArthurWalpole, the lead
chemist on the tamoxifen project,
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wondered whether the drug might
provide the answer to one half of
Beatson’s puzzle. He arranged for a
clinical trial at Manchester’s Christie
Hospital where forty-six women
suffering from “advanced, metastatic
breast cancer,” many of them doomed,
were administered the drug.Ten
responded almost immediately with
shrinking tumors and, while many of
the patients did subsequently relapse,
trial and error had proved that a drug,
“not a cellular poison,” could drive
“metastatic tumors into remission.”
ER positive cells responded to
tamoxifen; ER negative cells didn’t.
Mukherjee notes that “for the first
time in the history of cancer, a drug,
its target, and a cancer cell had been
conjoined by a core molecular logic.”
The rediscovery by Axel Ullrich, a
researcher at Genentech, of what’s
termed an oncogene began to fill in
more pieces to the puzzle.An oncogene,
if I understand correctly, signals a cell to
grow unchecked; the trick was to find
some means for rendering the oncogene
inactive. One oncogene designated
Her-2 turned out to associate itself with
aggressive breast cancer. Dennis Slamon,

a UCLA oncologist described by one
reporter as a “velvet jackhammer,” had
heard Ullrich speak about his discovery
and realized that the Genentech scientists didn’t know how to proceed with
their knowledge. In collaboration with
Genentech immunologists, Slamon
developed an antibody that inactivated
Her-2 in mouse tumors and, in his
UCLA lab he treated breast cancer
cells with the antibody: they “stopped
growing, involuted and died”
However, by the late 1980’s Genentech
had started “abandoning its interest in
cancer” for fear that investing millions in
a drug that might fail would cripple the
company’s finances. Ullrich left the
company to work in a German
Laboratory. Slamon and a small group
of sympathetic Genentech scientists
worked tirelessly to keep the project
alive.The group ultimately in 1990
“humanized” the mouse antibody into
a potential drug which soon took the
name Herceptin (Her-2, intercept, and
inhibitor). Genentech ultimately agreed
to conduct clinical trials. Mukherjee
recounts the events of Herceptin’s
clinical trials where the drug proved
effective in prolonging the lives of

women with aggressive metastatic breast
cancers. News of the drug’s effectiveness
brought advocacy groups to pressure
the FDA for rapid approval. Herceptin,
marketed as Trastuzumab, is now routinely prescribed.The fact, however, that
the prescribed Herceptin regimen is
substantially cheaper in Australia than
in the US has moved the controversy
into a new arena.
The Emperor of All Maladies ranges
widely over the history of cancer.
Mukherjee understands the paradox of
cancer, which “consumes that which it
is nourished by”; in his narratives about
individual patients like Carla, he never
loses sight that those researchers and
physicians like himself who consume
their lives working in laboratories and
clinics are driven to alleviate the human
suffering caused by this disease.

Charles Angell is a Professor of English
and Book Review Editor of Bridgewater
Review.

I read The Emperor of All Maladies on my Amazon
Kindle. Though a book lover, I felt I needed to
become familiar with the advantages and disadvantages of eBook technology. For books one
wants to read but not necessarily own, the eBook
is ideal. One can download the book, read it, and
archive it. The Kindle allows one to make bookmarks and enter notes, two functions I’m still
learning how to use. For one used to having a book
with an index one can consult easily, the Kindle
book’s index is not so readily accessible. For academics, an agreed upon protocol for citing eBooks
will need developing. However, given the everincreasing expense of the printed book, the eBook
technology reduces text cost and, insofar as
schools are concerned, will allow teachers to
assign books not readily available to students.
Used properly, the eBook may offer more pedagogical benefits than a required laptop computer.
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